Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvia Zanon

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Cancer Chemotherapy and Pharmacology|March 12, 2020
Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinomaMichele Reni, Umberto Peretti, Silvia Zanon, et al.
Revista Brasileira De Terapia Intensiva|October 11, 2014
Star fruit intoxication in a chronic renal failure patient: case reportFábio Gonzaga Moreira, Rodrigo Lerário Iervolino, Silvia Zanon Dall'Orto, et al.
British Journal of Cancer|July 13, 2016
Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinomaMichele Reni, Gianpaolo Balzano, Silvia Zanon, et al.
The Lancet. Gastroenterology & Hepatology|September 18, 2018
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trialMichele Reni, Silvia Zanon, Umberto Peretti, et al.
Cancer Chemotherapy and Pharmacology|November 7, 2020
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patientsMarina Macchini, Umberto Peretti, Giulia Orsi, et al.
Nuclear Medicine Communications|August 1, 2019
Early variation of 18-fluorine-labelled fluorodeoxyglucose PET-derived parameters after chemoradiotherapy as predictors of survival in locally advanced pancreatic carcinoma patientsElena Incerti, Emilia G Vanoli, Sara Broggi, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2018
A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinomaMichele Reni, Silvia Zanon, Gianpaolo Balzano, et al.
The Lancet. Gastroenterology & Hepatology|April 8, 2018
Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trialMichele Reni, Gianpaolo Balzano, Silvia Zanon, et al.
American Journal of Hematology|February 15, 2025
Isolated Cerebral Myeloid Sarcoma in an Allogeneic Stem Cell Transplant RecipientGabriele Magliano, Silvia Zanon, Rachele de Domenico, et al.
Bone Marrow Transplantation|June 24, 2026
A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40-65 in first complete remissionDaniele Avenoso, Vera Radici, Alessandro Leoni, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Cancer Chemotherapy and Pharmacology|March 12, 2020
Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinomaMichele Reni, Umberto Peretti, Silvia Zanon, et al.
Revista Brasileira De Terapia Intensiva|October 11, 2014
Star fruit intoxication in a chronic renal failure patient: case reportFábio Gonzaga Moreira, Rodrigo Lerário Iervolino, Silvia Zanon Dall'Orto, et al.
British Journal of Cancer|July 13, 2016
Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinomaMichele Reni, Gianpaolo Balzano, Silvia Zanon, et al.
The Lancet. Gastroenterology & Hepatology|September 18, 2018
Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trialMichele Reni, Silvia Zanon, Umberto Peretti, et al.
Cancer Chemotherapy and Pharmacology|November 7, 2020
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patientsMarina Macchini, Umberto Peretti, Giulia Orsi, et al.
Nuclear Medicine Communications|August 1, 2019
Early variation of 18-fluorine-labelled fluorodeoxyglucose PET-derived parameters after chemoradiotherapy as predictors of survival in locally advanced pancreatic carcinoma patientsElena Incerti, Emilia G Vanoli, Sara Broggi, et al.
European Journal of Cancer (Oxford, England : 1990)|August 28, 2018
A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinomaMichele Reni, Silvia Zanon, Gianpaolo Balzano, et al.
The Lancet. Gastroenterology & Hepatology|April 8, 2018
Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trialMichele Reni, Gianpaolo Balzano, Silvia Zanon, et al.
American Journal of Hematology|February 15, 2025
Isolated Cerebral Myeloid Sarcoma in an Allogeneic Stem Cell Transplant RecipientGabriele Magliano, Silvia Zanon, Rachele de Domenico, et al.
Bone Marrow Transplantation|June 24, 2026
A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40-65 in first complete remissionDaniele Avenoso, Vera Radici, Alessandro Leoni, et al.
Pageof 2